CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today ...
Approval was based on the phase 3 ENERGIZE and ENERGIZE-T studies evaluating the safety and efficacy of mitapivat in adults with alpha- or beta-thalassemia.
– Tebapivat Phase 1 Data in Sickle Cell Disease and Phase 2b Trial-in-progress Update in Lower-risk Myelodysplastic Syndromes will be Presented and Published – – Live and Webcast Investor Event with ...
Agios Pharmaceuticals announced that it will present new data on its pyruvate kinase activators, mitapivat and tebapivat, during the 30th European Hematology Association (EHA) Congress in Milan from ...
India Today on MSN
US approves first pill for thalassemia anemia: What this means for India
The US FDA has approved mitapivat, the first oral medicine for treating anemia caused by thalassemia. At present, mitapivat ...
There are currently no FDA-approved oral treatments for non-transfusion-dependent thalassemia. Mitapivat was found to be an effective oral treatment for non-transfusion-dependent (NTD) alpha- or ...
6don MSN
FDA approves first oral drug for thalassemia anemia, offering new hope beyond blood transfusions
The US FDA has approved Mitapivat (Aqvesme), the first oral therapy for anemia in adults with alpha or beta thalassemia, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback